Top Banner
Optical Coherence Tomography: Optical Biopsy with a Short Photonic Needle? I.K. Jang, MD Massachusetts General Hospital Harvard Medical School The 3 rd Vulnerable Plaque Symposium Atlanta, March 16, 2002
26

058 optical coherence tomography

Jan 20, 2017

Download

Health & Medicine

SHAPE Society
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: 058 optical coherence tomography

Optical Coherence Tomography: Optical Biopsy with a Short

Photonic Needle?

I.K. Jang, MDMassachusetts General Hospital

Harvard Medical School

The 3rd Vulnerable Plaque SymposiumAtlanta, March 16, 2002

Page 2: 058 optical coherence tomography

Optical Coherence Tomography

• Optical analog of ultrasound

• Cross-sectional imaging

• 10 µm resolution

• 2 mm penetration depth

Low signal High signal

Page 3: 058 optical coherence tomography

MGH OCT System Technical Data

Optical wavelength :

Image acquisition rate :

Catheter:

Axial Resolution :

Transverse Resolution :

Data storage :

1300 nm

4-8 images / sec

3.0 F

10 m

25 m

Digital

Page 4: 058 optical coherence tomography

Ex Vivo StudyAim

Establish OCT criteria for plaque characterization

Materials and Methods• 357 arterial segments from 90 cadavers

– 78 Coronary; 86 Carotid; 143 Aorta• training set, n=50

validation set, n = 307

• Specimen registration• OCT imaging• Histology processing• Correlation of OCT with histology

Page 5: 058 optical coherence tomography

Ex Vivo Study

Type NumberFibrous 11 (22%)Calcific 27 (54%)Lipid pool 12 (24%)

Type NumberFibrous 67 (22%)Calcific 167 (54%)

Lipid pool 73 (24%)

Validation Set (n = 307)Training Set (n = 50)

Histologic Diagnoses

Page 6: 058 optical coherence tomography

OCT Characteristics

lp

lp

Homogeneous,Signal-rich

Fibrous Lipid

Echolucent, Diffuse Borders

Echolucent, Sharp Borders

Calcific500 µm

Page 7: 058 optical coherence tomography

Intimal Hyperplasia

Low signal High signal

Page 8: 058 optical coherence tomography

Fibrous Plaque

F

IMA

F

EELIEL

Page 9: 058 optical coherence tomography

lp

n

lp

Lipid-Rich Plaque(with neovascularization)

Page 10: 058 optical coherence tomography

Calcific Plaque

C C

Page 11: 058 optical coherence tomography

Ex Vivo Study Results

SENS .87 PPV .88SPEC .97 NPV .96

SENS .95 PPV 1.0SPEC 1.0 NPV .95

SENS .92 PPV .81SPEC .94 NPV .97

Accuracy Statistics

Fibrous

Calcific

Lipid pool

Interobserver = 0.88, Intraobserver = 0.91

Page 12: 058 optical coherence tomography

Clinical Study 1

Feasibility and Safety:Pre and Post PCI

Page 13: 058 optical coherence tomography

Pilot Human Study

Aim: Test feasibility and safety of OCT in patients

Methods• 10 patients (average age 59, 8M/2F)• Coronary angiogrpahy• IVUS + OCT imaging (3.2 F catheter)• PCI• Repeat IVUS + OCT Imaging

Page 14: 058 optical coherence tomography

Fibrous Plaque

Page 15: 058 optical coherence tomography

Fibrous Plaque

Page 16: 058 optical coherence tomography

Lipid-rich Plaque

Page 17: 058 optical coherence tomography

Lipid Rich Plaque

g

lplp

f

g

2x

ma

i

iel eel

f

OCT IVUS

Page 18: 058 optical coherence tomography

Fibrous Plaque with Calcium

Page 19: 058 optical coherence tomography

Fibrous Plaque with Calcium

Page 20: 058 optical coherence tomography

Post balloon Dissection

Page 21: 058 optical coherence tomography

Cutting balloon

Page 22: 058 optical coherence tomography

Stent

Page 23: 058 optical coherence tomography

Stent

Page 24: 058 optical coherence tomography

Stent

Page 25: 058 optical coherence tomography

Pilot Human Study Results No OCT related complications

Variety of pathology imaged and compared with IVUS• 10 patients with 28 plaque segments• 8 dissections• 13 stent locations

Problems• Obstruction by blood• Motion artifacts

Page 26: 058 optical coherence tomography

Acknowledgements

Massachusetts General HospitalCardiology DivisionH. Yabushita, B. MacNeill, H. Lowe, M. Hayashi, S. Clarke, E. Pomerantsev, D. DeJoseph, I.K. Jang

Wellman Laboratories of Photomedicine B.E. Bouma, M. Shishkov, C. Kauffman, N. Iftima, G.J. Tearney

Dept. of PathologyS. Houser, H.T. Aretz

CIMITJ. Muller, T. Brady, J. Rosen

Guidant CorporationD. Kilpatrick, J. Ellis, R. Jones, T. Linnemeier